share_log

Morgan Stanley Initiates Coverage On Senti Biosciences With Equal-Weight Rating, Announces Price Target of $7.5

Benzinga Real-time News ·  Oct 7, 2022 06:12

Morgan Stanley analyst Michael Ulz initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight rating and announces Price Target of $7.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment